Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

 Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Shots:

  • Takeda has submitted an NDA to MHLW to import and distribute Moderna’s (mRNA-1273/ TAK-919) in Japan
  • Takeda is conducting a P- I/II study assessing the safety and immunogenicity of two vaccinations of TAK-919 (100μg, given 28 days apart) in 200 participants aged ≥20yrs. followed through 12mos. after the second vaccination. Takeda has completed enrollment in the P-I/II study of TAK-919 in Feb’2021
  • Takeda will import and distribute 50M doses of Moderna’s COVID-19 vaccine candidate in H1’21, following the pending licensure in Japan

Click here ­to­ read full press release/ article | Ref: Moderna | Image: Daytona Beach News- Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post